Comparative Pharmacology
Head-to-head clinical analysis: TPOXX versus VALCYTE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TPOXX versus VALCYTE.
TPOXX vs VALCYTE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
TPOXX (tecovirimat) inhibits the orthopoxvirus VP37 envelope protein, preventing viral egress from infected cells and reducing viral spread.
Valganciclovir is an L-valyl ester (prodrug) of ganciclovir. After oral administration, it is rapidly hydrolyzed to ganciclovir. Ganciclovir is phosphorylated to ganciclovir triphosphate, which inhibits viral DNA synthesis by competitive inhibition of viral DNA polymerase and incorporation into viral DNA, causing chain termination.
600 mg orally twice daily for 14 days.
For cytomegalovirus (CMV) retinitis in immunocompromised patients: 900 mg orally twice daily for 21 days, then 900 mg once daily as maintenance. For prevention of CMV in transplant recipients: 900 mg orally once daily starting within 10 days of transplant, continuing up to 100 days post-transplant.
None Documented
None Documented
Terminal half-life ~19 hours (range 10–48 h) in healthy adults; prolonged in renal impairment (up to ~100 h).
Terminal elimination half-life: 3-5 hours (valganciclovir) and 3.5-4.5 hours (ganciclovir, after conversion). In patients with renal impairment, half-life is prolonged: up to 10-30 hours depending on creatinine clearance. Hemodialysis reduces half-life to approximately 4-5 hours.
Fecal (primarily as unchanged drug, ~75%); renal (~25%, mostly as metabolites; <2% unchanged in urine).
Renal excretion (primarily glomerular filtration and tubular secretion). Approximately 82-90% of the administered dose is recovered unchanged in urine. Fecal excretion is minimal (<5%). Biliary excretion is negligible.
Category C
Category C
Antiviral Agent
Antiviral Agent